Recovery of sugammadex reversal of residual nueromuscular blockade influenced by dexmetomidine combined with sevoflurane in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031156

Enrollment

Unknown

Registered

2020-03-23

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inguinal hernia, hydrocele of tunica vaginalis, OSAS, etc

Interventions

A:nasal dexmetomidine 1 mcg/kg

B:nasal dexmetomidine 0.75 mcg/kg

C:nasal saline

Eligibility

Sex/Gender

All

Age

1 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 1-12years; 2. ASA I or II; 3. Operative time<120min; 4. The subjects legally authorized representative has given written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. The subject is allergic to or has a contraindication to any of the drugs used in the study. 2. History of neuromuscular disease; 3. History of congenital heart disease; 4. Recent history of upper respiratory infections; 5. Participate in other clinical trials.

Design outcomes

Primary

Measure	Time frame
TOF ratio;	—

Secondary

Measure	Time frame
time of extubation;	—

Countries

China

Contacts

Public ContactXue Bin

Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine

icecreams2000@163.com+86 13585634772

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026